Guided Therapeutics (GTHP) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 14, 2022
Cover [Abstract]
Entity Registrant Name	GUIDED THERAPEUTICS, INC.
Entity Central Index Key	0000924515
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		48,578,721
Document Quarterly Report	true
Entity File Number	0-22179
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	58-2029543
Entity Interactive Data Current	Yes
Entity Address Address Line 1	5835 Peachtree Corners East
Entity Address Address Line 2	Suite B
Entity Address City Or Town	Norcross
Entity Address State Or Province	GA
Entity Address Postal Zip Code	30092
City Area Code	770
Local Phone Number	242-8723
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 2,697	$ 643
Accounts receivable, net of allowance for doubtful accounts of $48 and $126 at September 30, 2022 and December 31, 2021, respectively	29	46
Inventory, net of reserves of $785 at September 30, 2022 and December 31, 2021	596	571
Other current assets	169	377
Total current assets	3,491	1,637
Non-Current Assets:
Property and equipment, net	42	14
Operating lease right-of-use assets, net of amortization	321	372
Other assets	17	17
Total non-current assets	380	403
TOTAL ASSETS	3,871	2,040
Current Liabilities:
Accounts payable	2,217	2,362
Accounts payable, related parties	60	87
Accrued liabilities	1,050	1,768
Deferred revenue	509	337
Current portion of lease liability	76	67
Current portion of long-term debt	32	88
Current portion of long-term debt, related parties	497	0
Short-term notes payable	90	48
Short-term notes payable, related parties	17	40
Convertible notes payable in default	0	161
Short-term convertible notes payable, including non-convertible penalty	579	736
Derivative liability	19	0
Total current liabilities	5,146	5,694
Long-Term Liabilities
Long-term lease liabilities	267	325
Derivative liability	0	32
Long-term convertible debt	1,017	820
Long-term debt	0	22
Long-term debt, related parties	92	592
Total long-term liabilities	1,376	1,791
Total liabilities	6,522	7,485
STOCKHOLDERS DEFICIT:
Common stock, $.001 par value; 500,000 shares authorized, 27,583 and 13,673 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	3,432	3,403
Treasury stock at cost	(132)	(132)
Additional paid-in capital	136,366	126,800
Accumulated deficit	(145,502)	(142,387)
Total stockholders deficit	(2,651)	(5,445)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	3,871	2,040
Series C Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	105	105
Series C1 Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	170	170
Series C2 Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	531	531
Series D Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	159	276
Series E Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	839	1,639
Series F Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	892	1,187
Series F2 Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	489	2,963
Series G Convertible Preferred Shares [Member]
STOCKHOLDERS DEFICIT:
Preferred Stock Value	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accounts receivable, net of allowance	$ 48,000	$ 126,000
Inventory, net of reserves	$ 785,000	$ 785,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	500,000,000	500,000,000
Common stock, issued	27,583,000	13,673,000
Common stock, outstanding	27,583,000	13,673,000
Series C Convertible Preferred Shares [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	9,000	9,000
Preferred stock, issued	300	300
Preferred stock, outstanding	300	300
Preferred stock, liquidation preference	286,000	286,000
Series C-1 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	20,300	20,300
Preferred stock, issued	1,000	1,000
Preferred stock, outstanding	1,000	1,000
Preferred stock, liquidation preference	$ 1,049,000	$ 1,049,000
Series C-2 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	3,300	3,300
Preferred stock, outstanding	3,300	3,300
Preferred stock, liquidation preference	$ 3,263,000	$ 3,263,000
Series D Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	6,000	6,000
Preferred stock, issued	400	800
Preferred stock, outstanding	400	800
Preferred stock, liquidation preference	$ 438,000	$ 763,000
Series E Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, issued	900	1,700
Preferred stock, outstanding	900	1,700
Preferred stock, liquidation preference	$ 888,000	$ 1,736,000
Series F Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	1,500	1,500
Preferred stock, issued	1,100	1,400
Preferred stock, outstanding	1,100	1,400
Preferred stock, liquidation preference	$ 1,071,000	$ 1,426,000
Series F-2 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, issued	500	3,200
Preferred stock, outstanding	500	3,200
Preferred stock, liquidation preference	$ 535,000	$ 3,237,000
Series G Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Preferred stock, liquidation preference	$ 0	$ 0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Sales - devices and disposables	$ 3	$ 19	$ 13	$ 21
Cost of goods sold	0	42	2	42
Gross profit (loss)	3	(23)	11	(21)
Operating expenses:
Research and development	8	16	38	52
Sales and marketing	52	41	129	107
General and administrative	1,167	407	2,229	1,747
Total operating expenses	1,227	464	2,396	1,906
Loss from operations	(1,224)	(487)	(2,385)	(1,927)
Other income (expenses):
Interest expense	(155)	(594)	(512)	(1,050)
Change in fair value of derivative liability	5	(1)	13	(89)
Gain from extinguishment of debt	270	763	345	578
Change in fair value of warrants	0	0	0	448
Other income	2	387	5	414
Total other income (expense)	122	555	(149)	301
Loss before income taxes	(1,102)	68	(2,534)	(1,626)
Provision for income taxes	0	0	0	0
Net income (loss)	1,102	68	(2,534)	(1,626)
Preferred stock dividends	(48)	(119)	(581)	(296)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (1,054)	$ (51)	$ (3,115)	$ (1,922)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.03)	$ 0	$ (0.11)	$ (0.14)
Diluted	$ (0.03)	$ 0	$ (0.11)	$ (0.14)
Weighted average shares outstanding
Basic	34,829	13,417	27,335	13,291
Diluted	34,829	13,417	27,335	13,291

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT( Unaudited) - USD ($)	Total	Preferred Stock Series C [Member]	Preferred Stock Series C1 [Member]	Preferred Stock Series C2 [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Preferred Stock Series F [Member]	Preferred Stock Series F-2 [Member]	Common Stock [Member]	Additional Paid-In Capital	Treasury Stock [Member]	Retained Earnings (Accumulated Deficit)	Preferred Stock Series G [Member]
Balance, shares at Dec. 31, 2020			1,000	3,000	1,000	2,000			13,138,000
Balance, amount at Dec. 31, 2020	$ (10,855,000)	$ 105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 0	$ 0	$ 3,403,000	$ 123,109,000	$ (132,000)	$ (139,956,000)	$ 0
Series F preferred offering							1,000
Series F preferred offering, amount	1,195,000					0	$ 1,195,000	$ 0		0			$ 0
Series F-2 preferred offering,share								1,000
Series F-2 preferred offering	404,000	0	0	0	0			$ 404,000		0
Conversion of debt and expenses for Series F-2 preferred stock,share								2,000
Conversion of debt and expenses for Series F-2 preferred stock,Amount	2,559,000	0	0	0	0			$ 2,000
Issuance of common stock for Series D preferred dividends,share									83,000
Issuance of common stock for Series D preferred dividends, amount	39,000									39,000
Issuance of common stock for Series E preferred dividends, shares									288,000
Issuance of common stock for Series E preferred dividends, amount	118,000									118,000
Series G preferred offering													153,000
Series G preferred offering, amount	(1,626,000)	0	0	0	$ 0					0		(1,626,000)
Series G redemption amount	178,000	0	$ 0	$ 0						0
Series G redemption, share													(153,000)
Issuance of common stock to finders,share									98,000
Issuance of common stock to finders	54,000					$ 0				54,000
Issuance of warrants to consultants	1,093,000									1,093,000
Warrants issued	304,000									304,000
Conversions of warrants from liability to equity	1,755,000									1,755,000
Stock-based compensation	178,000									178,000
Accrued preferred dividends	(296,000)									0		(296,000)
Net loss	(1,626,000)									0		(1,626,000)
Balance, shares at Sep. 30, 2021			1,000	3,000	1,000	2,000	1,000	3,000	13,607,000
Balance, amount at Sep. 30, 2021	(7,746,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,195,000	$ 2,963,000	$ 3,403,000	126,650,000	(132,000)	(141,929,000)	$ 0
Balance, shares at Jun. 30, 2021			1,000	3,000	1,000	2,000	1,000	3,000	13,297,000				62,000
Balance, amount at Jun. 30, 2021	(7,992,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,195,000	$ 2,963,000	$ 3,403,000	126,353,000	(132,000)	(141,878,000)	$ 0
Issuance of common stock for Series D preferred dividends, amount	11,000									11,000
Series G redemption, share													62,000
Net loss	68,000	0	0	0	0	0	0	0	0	0	0	68,000	$ 0
Stock-based compensation	56,000	0	0	0	0	0	0	0	0	56,000	0	0	0
Issuance of common stock for Series E preferred dividends	118,000	0	0	0	0	0	0	0	288,000	118,000			0
Accrued preferred dividends	(119,000)	0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	0	0	0	(119,000)	0
Issuance of common stock for Series D preferred dividends									$ 22,000
Balance, shares at Sep. 30, 2021			1,000	3,000	1,000	2,000	1,000	3,000	13,607,000
Balance, amount at Sep. 30, 2021	(7,746,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,195,000	$ 2,963,000	$ 3,403,000	126,650,000	(132,000)	(141,929,000)	$ 0
Balance, shares at Dec. 31, 2021			1,000	3,000	1,000	2,000	1,000	3,000	13,674,000
Balance, amount at Dec. 31, 2021	(5,445,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,187,000	$ 2,963,000	$ 3,403,000	126,800,000	(132,000)	(142,387,000)
Accrued preferred dividends		0	0	0	0	0	0	0
Net loss	(2,534,000)	0	0	0	0	0	0	0		0		(2,534,000)
Stock-based compensation	132,000								0	132,000	0	0
Accrued preferred dividends	(581,000)								$ 0	0	0	(581,000)
Issuances of warrants to investors	1,796,000	0	0	0	0	0	0	0		1,796,000
Conversion of Series D preferred stock to common stock		0	0	0	(117,000)	0	0	0
Issuances of warrants to consultants		0	$ 0	$ 0	$ 0	0	0	0
Common stock warrants exercised, shares									5,128,000
Common stock warrants exercised, amount	846,000								$ 5,000	841,000	0	0
Issuances of common stock to investors, shares									6,637,000
Issuances of common stock to investors, amount	1,396,000								$ 7,000	1,389,000	0	0
Issuance of common stock for payment of Series D preferred dividends, shares									65,000
Issuance of common stock for payment of Series D preferred dividends, amount	39,000								$ 0	39,000	0	0
Issuance of common stock for payment of Series E preferred dividends, shares									181,000
Issuance of common stock for payment of Series E preferred dividends, amount	102,000								$ 0	102,000	0	0
Issuance of common stock for payment of Series F preferred dividends, shares									161,000
Issuance of common stock for payment of Series F preferred dividends, amount	107,000								$ 0	107,000	0	0
Issuance of common stock for payment of Series F-2 preferred dividends, shares									114,000
Issuance of common stock for payment of Series F-2 preferred dividends, amount									242,000
Issuance of common stock for payment of interest	150,000									150,000
Issuance of common stock for payment of interest, amount	150,000								$ 0	150,000	0	0
Issuance of common stock for Series F and Series F-2 one-time 15% dividends, shares									624,000
Issuance of common stock for Series F and Series F-2 one-time 15% dividends, amount	400,000								$ 1,000	399,000	0	0
Conversion of Series D preferred stock to common stock, shares									975,000
Conversion of Series D preferred stock to common stock, amount	1,000					$ 1,000			$ 1,000	117,000	0	0
Conversion of Series E preferred stock to common stock, shares						(800,000)			3,390,000
Conversion of Series E preferred stock to common stock, amount	0						$ (292,000)		$ 3,000	797,000	0	0
Conversion of Series F preferred stock to common stock, shares									1,420,000
Conversion of Series F preferred stock to common stock, amount	0							$ (2,474,000)	$ 1,000	294,000	0	0
Conversion of Series F-2 preferred stock to common stock, shares								(3,000)	10,808,000
Conversion of Series F-2 preferred stock to common stock, amount	0								$ 11,000	2,463,000	0	0
Balance, shares at Sep. 30, 2022			1,000	3,000	1,000	1,000	1,000		43,419,000
Balance, amount at Sep. 30, 2022	(2,651,000)	105,000	$ 170,000	$ 531,000	$ 159,000	$ 839,000	$ 892,000	$ 489,000	$ 3,432,000	136,366,000	(132,000)	(145,502,000)
Balance, shares at Jun. 30, 2022			1,000	3,000	1,000	1,000	1,000	3,000	27,583,000
Balance, amount at Jun. 30, 2022	(5,766,000)	105,000	$ 170,000	$ 531,000	$ 159,000	$ 839,000	$ 892,000	$ 2,536,000	$ 3,416,000	130,166,000	(132,000)	(144,448,000)
Net loss	(1,102,000)	0	0	0	0	0	0	0	0	0	0	(1,102,000)
Stock-based compensation	44,000	0	0	0	0	0	0	0	0	44,000	0	0
Accrued preferred dividends	48,000	0	0	0	0	0	0	0	0	0	0	48,000
Issuances of warrants to investors	1,796,000	0	0	0	0	0	0	0	0	1,796,000	0	0
Issuances of warrants to consultants	786,000	0	0	0	0	0	0	0	$ 0	786,000	0	0
Issuances of common stock to investors, shares									6,637,000
Issuances of common stock to investors, amount	1,396,000								$ 7,000	1,389,000	0	0
Issuance of common stock for payment of Series D preferred dividends, amount	10,000	0							0	10,000	0	0
Issuance of common stock for payment of interest, amount	70,000	0	0	0	0	0	0	$ 0	$ 0	70,000	0	0
Conversion of Series F-2 preferred stock to common stock, shares								3,000	8,944,000
Conversion of Series F-2 preferred stock to common stock, amount	0	0	0	0	0	0	0	$ (2,047,000)	$ 9,000	2,038,000	0	0
Issuances of common stock to investors		0	0	0	0	0	0	0
Issuance of common stock for payment of Series D preferred dividends, share									17,000
Issuance of common stock for payment of Series E preferred dividends, share									117,000
Issuance of common stock for payment of Series E preferred dividends, amount	67,000	0	$ 0	$ 0	$ 0	$ 0	$ 0	0	$ 0	67,000	0	0
Issuance of common stock for payment of interest,Share									121,000
Balance, shares at Sep. 30, 2022			1,000	3,000	1,000	1,000	1,000		43,419,000
Balance, amount at Sep. 30, 2022	$ (2,651,000)	$ 105,000	$ 170,000	$ 531,000	$ 159,000	$ 839,000	$ 892,000	$ 489,000	$ 3,432,000	$ 136,366,000	$ (132,000)	$ (145,502,000)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,534)	$ (1,626)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1	1
Amortization of debt issuance costs and discounts	111	250
Amortization of beneficial conversion feature	0	37
Stock based compensation	132	178
Change in fair value of warrants	0	(448)
Extinguishment of derivative liability	0	(84)
Change in fair value of derivative liability	(13)	89
Amortization of lease right-of-use-asset	50	66
Expense for warrants issued to consultants	865	585
Gain from extinguishment of debt	(345)	(578)
Other non-cash expenses	156	109
Change in operating assets and liabilities:
Accounts receivable	16	0
Inventory	(25)	14
Other current assets	332	(88)
Other non-current assets	0	(17)
Accounts payable and accrued liabilities	(7)	(435)
Lease liabilities	(51)	(41)
Deferred revenue	172	237
NET CASH USED IN OPERATING ACTIVITIES	(1,140)	(1,751)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(28)	(10)
NET CASH USED FOR INVESTING ACTIVITIES	(28)	(10)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from warrant exercises	495	0
Proceeds from debt financing	0	1,248
Payments made on notes payable	(465)	(1,415)
Payments of debt issuance costs	0	(86)
Note payable default penalty	0	398
Proceeds from issuances of common stock, net of costs	1,396	0
Proceeds from issuances of warrants, net of costs	1,796	0
Proceeds from Series F offering, net of costs	0	1,436
Proceeds from Series F-2 offering, net of costs	0	539
Proceeds from Series G offering, net of costs	0	125
Redemption of Series G preferred stock	0	(125)
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,222	2,120
NET CHANGE IN CASH	2,054	359
Cash at beginning of period	643	182
CASH AT END OF PERIOD	2,697	541
SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:
Cash paid for interest	89	552
SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Dividends on preferred stock	581	296
Settlement of interest through common stock issuance	151	0
Debt from related parties exchanged for Preferred series F-2 shares	0	323
Issuance of series F-2 preferred stock	0	2,236
Issuance of warrants to finders in connection with Series F and Series F-2 preferred stock	0	377
Settlement of dividends through common stock issuance	722	157
Settlement of accounts payable through common stock issuance	0	62
Warrants exchanged for fixed price warrants	0	1,755
Warrants issued with debt	0	304
Conversion of Series D Preferred Shares into common stock	118	0
Conversion of Series E Preferred Shares into common stock	800	0
Conversion of Series F Preferred Shares into common stock	296	0
Conversion of Series F-2 Preferred Shares into common stock	2,473	0
Directors and officers insurance obtained with financing	$ 124	$ 0

ORGANIZATION BACKGROUND AND BAS

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION
ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers. During the year ended December 31, 2021, the Board simultaneously approved a 1-for-20 reverse stock split of our common stock and decreased the total number of authorized common shares to 500,000,000. On November 18, 2021, the Company submitted an Issuer Company Related Action Notification regarding the reverse stock split to the Financial Industry Regulatory Authority (“FINRA”). On July 25, 2022, the Company filed a Certificate of Correction with the Secretary of State of Delaware to render null and void ab initio Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2021 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of September 30, 2022 and December 31, 2021, and the consolidated results of operations and cash flows for the three and nine-month periods ended September 30, 2022 and 2021 have been included. The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of September 30, 2022, it had an accumulated deficit of approximately $145.5 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development. The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At September 30, 2022, the Company had a negative working capital of approximately $1.8 million, accumulated deficit of $145.5 million and incurred a net loss including preferred dividends of $3.1 million for the nine months then ended. Stockholders’ deficit totaled approximately $2.7 million at September 30, 2022, primarily due to recurring net losses from operations. During the nine-month period ended September 30, 2022, the Company raised $3.2 million from the sale of common stock and warrants (net of expenses), and $495 thousand of proceeds from warrant exercises. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection. The Company had warrants exercisable for approximately 40.1 million shares of its common stock outstanding at September 30, 2022, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $8.6 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants. Accounting Standard Updates A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. Accounts Receivable The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable. Concentrations of Credit Risk The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk. Inventory Valuation All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. The following is a summary of the Company’s inventories as of September 30, 2022 and December 31, 2021: (in thousands) September 30, December 31, 2022 2021 Raw materials $ 1,274 $ 1,255 Work-in-progress 70 69 Finished goods 37 32 Inventory reserve (785 ) (785 ) Total inventory $ 596 $ 571 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. The following is a summary of the Company’s property and equipment at September 30, 2022 and December 31, 2021: (in thousands) September 30, December 31, 2022 2021 Equipment $ 1,085 $ 1,048 Software 653 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress - 8 Subtotal 1,791 1,761 Less accumulated depreciation (1,749 ) (1,747 ) Property, equipment and leasehold improvements, net $ 42 $ 14 Depreciation expense related to property and equipment for the three and nine months ended September 30, 2022 and 2021 was not material. Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount. Patent Costs (Principally Legal Fees) Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three and nine months ended September 30, 2022 and 2021. Leases A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 – Commitments and Contingencies. Accrued Liabilities Accrued liabilities as of September 30, 2022 and December 31, 2021 are summarized as follows: (in thousands) September 30, 2022 December 31, 2021 Compensation $ 488 $ 621 Professional fees 126 98 Stock subscription payable - 351 Interest 182 261 Vacation 42 39 Preferred dividends 190 349 Other accrued expenses 22 49 Total $ 1,050 $ 1,768 Stock Subscription Payable Cash received from investors for common stock shares that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet. Revenue Recognition ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the nine-month periods ended September 30, 2022 or 2021. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of September 30, 2022 and December 31, 2021, deferred revenue was $509,101 and $337,315, respectively. Significant Distributors As of September 30, 2022, accounts receivable outstanding was approximately $77,634. The gross outstanding amount was netted against a $48,172 allowance, leaving a balance of $29,462 which was from two distributors. As of December 31, 2021, accounts receivable outstanding was $171,153; the outstanding amount was netted against a $125,584 allowance, leaving a balance of $45,569, which was from two distributors. Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred. Income Taxes The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2021 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At September 30, 2022, the Company had approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations. Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model. Stock Based Compensation The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation – Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future. Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS
FAIR VALUE OF FINANCIAL INSTRUMENTS	3. FAIR VALUE OF FINANCIAL INSTRUMENTS The guidance for fair value measurements, ASC 820, Fair Value Measurements and Disclosures · Level 1–Quoted market prices in active markets for identical assets and liabilities; · Level 2–Inputs, other than level 1 inputs, either directly or indirectly observable; and · Level 3–Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use. The Company records its derivative activities at fair value. As of September 30, 2022 we had one instrument that we valued for the derivative liability associated with the bifurcated conversion option of a loan due to Auctus Funds, LLC (“Auctus”) in the amount of $298,884. There was no movement of instruments between fair value hierarchy tiers during the nine months ended September 30, 2022. The following tables present the fair value of those liabilities measured on a recurring basis as of September 30, 2022 and December 31, 2021: Fair Value at September 30, 2022 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $328,941 loan on December 17, 2019 $ - $ - $ (19 ) $ (19 ) Total short-term liabilities at fair value $ - $ - $ (19 ) $ (19 ) Fair Value at December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (32 ) (32 ) Total long-term liabilities at fair value $ - $ - $ (32 ) $ (32 ) The following is a summary of changes to Level 3 instruments during the nine months ended September 30, 2022: (in thousands) Senior Secured Derivative Total Balance, December 31, 2021 $ - $ (32 ) $ (32 ) Change in fair value during the period - 13 13 Balance, September 30, 2022 $ - $ (19 ) $ (19 )

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	9 Months Ended
	Sep. 30, 2022
STOCKHOLDERS DEFICIT:
STOCKHOLDERS' DEFICIT	4. STOCKHOLDERS’ DEFICIT Recent Sales of Securities On September 1, 2022, the Company entered into certain Securities Purchase Agreements (the “Agreement”) with certain accredited investors (the “Investors”), including Richard Blumberg, Michael James and John Imhoff, each a member of the Company’s Board of Directors, pursuant to which the Company issued 6,636,540 shares of its common stock, four year warrants to purchase an aggregate of 6,636,540 shares of Common Stock at $0.50 per share and 6,636,540 shares of Common Stock at $0.65 per share (the “Warrants”) for an aggregate purchase price of $3,318,270 (the “Transaction”). The Company has agreed that, as soon as practicable after the Closing Date, the Company shall file a Registration Statement on the appropriate form providing for the resale by the Investors of the Shares and the shares of Common Stock underlying the Warrants (the “Warrant Shares” and collectively with the Shares and the Warrants, the “Securities”) with the Securities and Exchange Commission. The Company shall use commercially reasonable efforts to cause such Registration Statement to become effective within 120 days of closing all rounds of this offering and to keep such Registration Statement effective at all times until the earlier of the date that the Shares and Warrant Shares may be resold pursuant to Rule 144 (assuming cashless exercise of the Warrants) and the date that no Investor owns any Securities. In the event that the Registration Statement is not effective on the 121st day following the Closing Date, the Company shall issue to each Investor an additional number of shares of Common Stock equal to 10% of the Shares issued to such Investor and an additional number of shares of Common Stock equal to 5% of the Shares issued to such Purchaser on each monthly anniversary thereafter until the earlier of the date the Registration Statement is effective and the date that the Shares and Warrant Shares may be resold pursuant to Rule 144 (assuming cashless exercise of the Warrants). The Company may avoid these penalties if, prior to the 121st day following the closing date of the last round of the offering, it files an application to list the Common Stock on a recognized Canadian Stock Exchange. In addition, if there is no effective Registration Statement covering the Warrant Shares after 180 th After payment of all fees and expenses relating to the transaction, the Company received net proceeds of approximately $3.2 million. The primary use of proceeds is to fund the completion and filing of clinical study data needed for FDA approval of the Company’s LuViva Advanced Cervical Scan. Additional use of proceeds is to support international distribution partners to grow sales throughout the remainder of 2022 and into 2023, as well as for general and administrative expenses. Common Stock The Company has authorized 500,000,000 shares of common stock with $0.001 par value. As of September 30, 2022 and December 31, 2021, 43,418,443 and 13,673,583 shares were issued and outstanding, respectively. During the nine months ended September 30, 2022, the Company issued 29,744,860 shares of common stock, as summarized below: Number of Shares Issuances of common stock to investors 6,636,540 Issuances of common stock for warrants exercised 5,127,923 Issuances of common stock for payment of Series D Preferred dividends 64,979 Issuances of common stock for payment of Series E Preferred dividends 179,858 Issuances of common stock for payment of Series F Preferred dividends 162,436 Issuances of common stock for payment of Series F-2 Preferred dividends 114,304 Issuances of common stock for payment of interest 241,914 Issuances of common stock for Series F one-time 15% dividend 255,401 Issuances of common stock for Series F-2 one-time 15% dividend 368,505 Conversion of Series D Preferred stock to common stock 975,000 Conversion of Series E Preferred stock to common stock 3,390,000 Conversion of Series F Preferred stock to common stock 1,420,000 Conversion of Series F-2 Preferred stock to common stock 10,808,000 Issued during the nine months ended September 30, 2022 29,744,860 Summary table of common stock share transactions: Shares outstanding at December 31, 2021 13,673,583 Issued in 2022 29,744,860 Shares outstanding at September 30, 2022 43,418,443 Preferred Stock The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. Series C Convertible Preferred Stock The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At September 30, 2022 and December 31, 2021, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 572,000 common stock shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. Unpaid accrued dividends were $120,120 as of September 30, 2022. Upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At September 30, 2022 and December 31, 2021, the “make-whole payment” for a converted share of Series C preferred stock would convert to 200 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. Series C1 Convertible Preferred Stock The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,049 shares were issued and outstanding at September 30, 2022 and December 31, 2021. In addition, some holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At September 30, 2022 and December 31, 2021, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock. At September 30, 2022 and December 31, 2021, there were 1,049.25 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C1 preferred stock would convert into approximately 2,000 shares of the Company’s common stock, for a total convertible of 2,098,500 common stock shares. The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt. Series C2 Convertible Preferred Stock On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, the Chief Operating Officer, and a director of the Company, pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At September 30, 2022 and December 31, 2021, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock, for a total convertible of 6,524,500 common stock shares. The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 Preferred Stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing. Series D Convertible Preferred Stock The Board designated 6,000 shares of preferred stock as Series D Preferred Stock, 438 and 763 of which remained outstanding as of September 30, 2022 and December 31, 2021, respectively. On January 8, 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 common stock shares, 1,526,000 common stock warrants, exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 common stock shares. The Series D Preferred Stock will have cumulative dividends at the rate per share of 10% per annum. The stated value and liquidation preference on the Series D Preferred Stock is $763. The 763 Series D Preferred Shares are convertible into debt at the option of the holder during a prescribed time period. If the Series D Preferred Shares are converted, the Series D preferences are surrendered and the debt is then secured by the Company’s assets. As of September 30, 2022, none of the remaining 438 Series D Preferred Shares have been converted to secured debt. Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the nine months ended September 30, 2022, the Company entered into various agreements with Series D Preferred shareholders, pursuant to which each holder separately agreed to exchange their Series D Preferred shares into the Company’s common shares (in accordance with their existing Series D Preferred Share Agreements). In addition, the holders agreed to exchange 650,000 common stock warrants with a strike price of $0.25 for 650,000 warrants with a strike price of $0.20, which were required to be immediately exercised. The Company received $130,000 from the holders for exercises of the aforementioned warrants. During the nine months ended September 30, 2022, the Company issued 975,000 common stock shares for the conversion of 325 shares of Series D Preferred Stock. During the nine months ended September 30, 2022, the Company issued 64,979 common stock shares for the payment of accrued Series D Preferred Stock dividends. As of September 30, 2022, the Company had accrued dividends for Series D preferred shares of $8,213. Series E Convertible Preferred Stock The Board designated 5,000 shares of preferred stock as Series E Preferred Stock, 888 and 1,736 of which remained outstanding as of September 30, 2022 and December 31, 2021, respectively. Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. Each share of Series E Preferred Stock has a par value of $0.001 per share and a Stated Value equal to $1,000, subject to increase set forth in its Certificate of Designation. Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, in shares of common stock. During the nine months ended September 30, 2022, the Company issued 3,390,000 common stock shares for the conversion of 848 shares of Series E Convertible Preferred Stock. During the nine months ended September 30, 2022, the Company issued 179,858 common stock shares for the payment of Series E Preferred Stock dividends accrued. As of September 30, 2022, the Company had accrued dividends for Series E preferred shares of $12,654. Series F Convertible Preferred Stock The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,071 and 1,426 of which were issued and outstanding as of September 30, 2022 and December 31, 2021, respectively. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,436,000 the Company issued 1,436 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 common stock shares. The Series F Preferred Stock is entitled to cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F Preferred Stock is $1,000. Each share of Series F Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F Preferred. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the nine months ended September 30, 2022, the Company issued 1,420,000 common stock shares for the conversion of 355 shares of Series F Preferred stock and 162,436 common stock shares for the payment of annual Series F Preferred Stock dividends. During the nine months ended September 30, 2022, the Company issued 255,401 common stock shares for the payment of a one-time, non-recurring 15% dividend to the Series F Preferred shareholders (as required by the Series F Certificate of Designation, in the event the Company did not uplist to the NASDAQ stock exchange or file its clinical data intended for FDA approval of LuViva by December 31, 2021). As of September 30, 2022, the Company had accrued dividends for Series F Preferred shares of $32,943. Series F-2 Convertible Preferred Stock The Company was oversubscribed for its Series F Convertible Preferred Stock, resulting in the requirement to file an additional Certificate of Designation for Series F-2 Convertible Preferred Stock with substantially the same terms as the Series F Convertible Preferred Stock. The Board designated 3,500 shares of preferred stock as Series F-2 Preferred Stock, 535 and 3,237 of which were issued and outstanding as of September 30, 2022 and December 31, 2021, respectively. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F-2 Investors”). In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred Stock is convertible into 4,000 common stock shares. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F-2 Preferred Stock is $1,000. Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holders of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the nine months ended September 30, 2022, the Company issued 10,808,000 common stock shares for the conversion of 2,702 shares of Series F-2 Preferred stock and 114,304 common stock shares for the payment of annual Series F-2 Preferred Stock dividends. During the nine months ended September 30, 2022, the Company issued 368,505 common stock shares for the payment of a one-time, non-recurring 15% dividend to the Series F-2 Preferred shareholders (as required by the Series F-2 Certificate of Designation in the event the Company did not uplist to the NASDAQ stock exchange or file its clinical data intended for FDA approval of LuViva by December 31, 2021). As of September 30, 2022, the Company had accrued dividends for Series F-2 Preferred shares of $16,242. Powerup (Series G Convertible Preferred Stock) During January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock, then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. The Company has redeemed all of the Series G preferred stock and the balance is paid. During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. Due to the mandatory redemption feature of the Series G preferred stock, the total amount of proceeds of $125,000 was recorded as a liability. On June 4, 2021, the Company redeemed the January 2021 investment of $75,000 for $114,597, this $39,597 difference was recorded as interest expense. On July 8, 2021, the Company redeemed the February 2021 investment of $50,000 for $78,094. The difference of $28,094 was recorded as interest expense. As of September 30, 2022 and December 31, 2021, the amount outstanding was nil. Warrants The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the nine months ended September 30, 2022: Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2021 27,669,634 $ 0.29 Warrants issued 15,323,080 0.54 Warrants expired (1,000 ) 0.50 Warrants exercised (2,934,324 ) 0.17 Outstanding, September 30, 2022 40,057,390 $ 0.40 During the three months ended September 30, 2022, the Company issued 13,273,080 warrants to investors (see “ Recent Sales of Securities” The Black-Scholes option pricing model was utilized to calculate the fair value of the warrants issued, with the following assumptions: September 30, 2022 Expected term (years) 3.8 Years Volatility 151.19 % Risk-free interest rate 3.30 % Dividend yield 0.00 % During the nine months ended September 30, 2022, the Company issued 5,127,923 common shares for warrants exercised, 2,193,599 of which were for warrants exercised prior to December 31, 2021. During December 31, 2021, the Company received approximately $351,000 from the holders for the exercise of 2,193,599 warrants, which was included in Accrued Liabilities as of December 31, 2021, pending issuance of the common shares.

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Sep. 30, 2022
STOCK OPTIONS
STOCK OPTIONS	5. STOCK OPTIONS The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The plan provides for stock options to be granted up to 10% of the outstanding common stock shares. There was no stock option activity during the nine months ended September 30, 2022. The following table summarizes the Company’s outstanding and exercisable stock options as of September 30, 2022: Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of September 30, 2022 1,500,000 $ 0.49 7.8 years $ - Options exercisable as of September 30, 2022 1,227,136 $ 0.49 7.8 years $ - The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price as of September 30, 2022 and the exercise price, multiplied by the number of options. As of September 30, 2022, there was $131,735 of unrecognized stock-based compensation expense. Such costs are expected to be recognized over a weighted average period of approximately one year. The weighted-average fair value of awards granted was nil and $0.47 during the nine months ended September 30, 2022 and 2021, respectively. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period.

LITIGATION AND CLAIMS

LITIGATION AND CLAIMS	9 Months Ended
	Sep. 30, 2022
LITIGATION AND CLAIMS
LITIGATION AND CLAIMS	6. LITIGATION AND CLAIMS From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year. As of September 30, 2022, and December 31, 2021, there was no accrual recorded for any potential losses related to pending litigation.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Operating Leases The below table presents total operating lease right-of-use assets and lease liabilities as of September 30, 2022: (in thousands) September 30, 2022 Operating lease right-of-use assets $ 321 Operating lease liabilities $ 343 The table below presents the maturities of operating lease liabilities as of September 30, 2022: (in thousands) Operating Lease Payments 2022 (remaining) $ 27 2023 112 2024 115 2025 118 2026 50 Total future lease payments 422 Less: discount (79 ) Total lease liabilities $ 343 The table below presents the weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities: Nine Months Ended September 30, 2022 Weighted average remaining lease term (years) 3.7 Weighted average discount rate 11.4 % Related Party Contracts On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee). On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company). On January 22, 2020, the Company entered into a promotional agreement with Blumberg & Bowles Consulting, LLC (“BB”), which is partially owned by Mr. Blumberg (a related party), to provide investor and public relations services for a period of two years. As compensation for these services, the Company will issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020, which resulted in a total fair value of $715,000. The Company did not appropriately expense the services received in connection with this agreement in 2020. During the nine months ended September 30, 2022, the Company recognized $79,444 of consulting expenses as a result of this agreement. Unrecognized consulting expense to be recognized under this agreement is nil as of September 30, 2022. During the three months ended September 30, 2022, the Company issued 875,000 warrants to Mr. Blumberg and 375,000 warrants Lee Bowles, a partial owner of BB. On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided $350,000, which was recorded to subscription receivable, to the Company in exchange for the following: (1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares. During the year ended December 31, 2021, the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. The Company confirmed an obligation to provide Mr. Blumberg with 950,000 fully transferrable warrants, which will expire on January 1, 2024 and have an exercise price of $0.25. Issuance of the warrants owed to Mr. Blumberg for his services is now predicated on the Company receiving funding receipts of $1,000,000, whether from a financing, series of financing, or gross sales. The amended agreement clarified that the warrants issued to Mr. Blumberg are compensation for services, which involve investor relations, marketing services and assisting the Company with obtaining financing. During the three months ended September 30, 2022, the Company obtained the requisite funding receipts and began recording expense for the warrants, which will be issued to Mr. Blumberg over a period of 24 months subsequent to the financing. During the three months ended September 30, 2022, the Company recognized $200,959 of expense for the warrants issued to Mr. Blumberg, which represents the pro-rata expense over the service term of his agreement. Other Commitments On July 24, 2019, Shandong Yaohua Medical Instrument Corporation (“SMI”), agreed to modify its existing agreement. Under the terms of this modification, the Company agreed to grant (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the following terms and conditions. First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 common stock shares. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides, then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacturing. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions. On August 12, 2021, the Company executed an amendment to its agreement with SMI, which established a payment schedule for the balance owed by SMI to the Company for outstanding purchase orders. The remaining balance owed for outstanding purchase orders was $26,965 as of September 30, 2022. Under the terms of the amended agreement, the parties agreed that if by October 30, 2022, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Although our Chinese partner SMI missed the date in the contract when they should have achieved commercialization, patients continue to be enrolled in the clinical studies in China which is sponsored and being paid for by SMI. We continue to work with SMI to finish the clinical study and are in discussions with them to provide additional time to achieve commercialization. We expect a revised contract reflecting these discussions to be signed in the fourth quarter of 2022. On August 24, 2022, the Company entered into an agreement with Ironstone Capital Corp. and Alan Grujic (the “Advisory Group”) whereby the Advisory Group agreed to perform marketing and investor relations services over a term of twelve months, commencing on the closing of a financing of at least $2.5 million. In consideration for these services, the Company issued 800,000 warrants with an exercise price of $0.50 to Mr. Grujic, which were due within 10 business days of closing the financing transaction (the “Transaction”) that took place in September 2022 (see Note 4, “ Recent sales of securities”) The Company estimated the fair value of the 800,000 warrants issued in September 2022 using the Black-Scholes option pricing model and recognized expense of $364,800 for the warrants during the three months ended September 30, 2022. The Company estimated the fair value of the warrants with market conditions using the Binomial Lattice model and recognized expense of $15,057 for the warrants (representing the pro rata expense over the expected term of the warrants) during the three months ended September 30, 2022. Contingencies The current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, could result in additional repercussions to the Company’s operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites. The future impact of the outbreak is highly uncertain and cannot be predicted, and the Company cannot provide any assurance that the outbreak will not have a material adverse impact on the Company’s operations or future results or filings with regulatory health authorities. The extent of the impact to the Company, if any, will depend on future developments, including actions taken to contain the coronavirus. The Russia-Ukraine conflict and the sanctions imposed in response to this crisis could result in repercussions to our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.

SHORT TERM NOTES PAYABLE

SHORT TERM NOTES PAYABLE	9 Months Ended
	Sep. 30, 2022
SHORT TERM NOTES PAYABLE
SHORT TERM NOTES PAYABLE	8. SHORT TERM NOTES PAYABLE On July 4, 2022, the Company entered into a premium finance agreement to finance its insurance policies totaling $123,889. Monthly payments of $11,409 are due on the note, including interest incurred at a rate of 5.0%. The note, which matures on May 4, 2023, had an outstanding balance of $89,947 as of September 30, 2022. On July 4, 2021, the Company entered into a premium finance agreement to finance its insurance policies totaling $117,560. The note required monthly payments of $11,968, including interest at 4.3%, until it matured in April of 2022. As of September 30, 2022, the outstanding balance was nil. During 2019, the Company issued promissory notes to Mr. Cartwright totaling $45,829. The notes were initially issued with 0% interest, however interest increased to 6.0% interest 90 days after the Company received $1,000,000 in financing proceeds. As of September 30, 2022, the balance on the notes was $17,154. On December 21, 2016 and January 19, 2017, the Company issued promissory notes to Mr. Fowler, in the amounts of approximately $12,500 and $13,900. The notes were initially issued with 0% interest and then went into default with an interest rate of 18%. As part of the March 22, 2021 exchange agreement these notes were combined into one short term note payable of $26,400 and $18,718 in principal and interest of the two previous notes, respectively, for a total balance of $45,118. The aforementioned agreement brought the note current. The note carried a monthly payment of $3,850, including interest at 6.0%, until it matured in March of 2022. As of September 30, 2022, the outstanding balance was nil. The following table summarizes short-term notes payable, including related parties: Short-term notes payable, including related parties September 30, 2022 December 31, 2021 Dr. Cartwright $ 17 $ 34 Mr. Fowler - 6 Premium Finance (insurance) 90 48 Short-term notes payable $ 107 $ 88 The short-term notes payable due to related parties was $17,154 at September 30, 2022 and $39,900 of the $87,514 balance at December 31, 2021.

AUCTUS CONVERTIBLE DEBT

AUCTUS CONVERTIBLE DEBT	9 Months Ended
	Sep. 30, 2022
AUCTUS CONVERTIBLE DEBT
AUCTUS CONVERTIBLE DEBT	9. AUCTUS CONVERTIBLE DEBT On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus. The convertible note issued to Auctus was for a total of $2.4 million. The note may not have been prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which was not paid when due shall bore interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices equaled the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020, the $0.15 price floor no longer applied. On September 1, 2022, the Company has agreed to exchange certain debt and equity owned by Auctus pursuant to an Exchange Agreement between the Company and Auctus (the “Exchange Agreement”). Immediately prior to the Exchange Agreement, Auctus held $1,228,183 of debt, including early prepayment penalty of $350,000, default premiums of $281,256, and $91,555 in interest payable. Auctus agreed to exchange the above balance for $710,911 in debt owed and to revert the May 27, 2020 note to its original term. Auctus currently holds 8,775,000 warrants that are priced between $0.15 and $0.20, and for the value of $1,950,000, which includes the value of the warrant and $350,000 in early prepayment penalty, agreed to exchange it for 3,900,000 common shares, warrants to purchase 3,900,000 common shares at $0.50 per share and warrants to purchase 3,900,000 common shares at $0.65 per share (the “Exchange”). Auctus agreed the equity instruments will be issued and exchanged in the fourth quarter of 2022 (see Note 12, “Subsequent Events”). As a result of the Exchange Agreement, Auctus forgave a default penalty of $225,444. In addition, the Company made a repayment of $221,467 to Auctus pursuant to the terms of the Exchange Agreement (the “Repayment”), of which $161,184 was applied to principal and penalties and $60,283 was applied to interest payable. Following the Exchange and Repayment, the Company will make payments to Auctus in four installments, over an 18-month period. The first installment of $125,000 was paid on September 8, 2022, of which $101,116 was applied to outstanding principal and $23,884 was applied to interest payable. The transaction was accounted for in accordance with ASC 470-60, Troubled Debt Restructurings (“TDR”) by Debtors. As a result of the Exchange Agreement, the Company recorded a gain on extinguishment of debt of $186,527 during the three months ended September 30, 2022. The following table summarizes the Auctus Convertible Notes Payable: September 30, 2022 December 31, 2021 Auctus Tranche 2 $ 329 $ 400 Auctus prepayment penalty 350 350 Auctus (March 31, 2020 Note) - 161 Debt discount and issuance costs to be amortized - (14 ) Auctus convertible notes payable $ 679 $ 897 As of September 30, 2022, $579,000 of the total balance owed to Auctus is included in “Short-term convertible notes payable, including non-convertible penalty” within the unaudited consolidated balance sheet. The remaining balance is included in “Long-term convertible debt” within the unaudited consolidated balance sheet. As of December 31, 2021, the $161,000 Auctus note was included in “Convertible notes payable in default” while the remaining balances were included in “Short-term convertible notes payable, including non-convertible penalty” within the consolidated balance sheet.

LONG TERM DEBT

LONG TERM DEBT	9 Months Ended
	Sep. 30, 2022
LONG TERM DEBT
LONG-TERM DEBT	10. LONG-TERM DEBT Long-term Debt – Related Parties On July 14, 2018, the Company entered into an exchange agreement with Dr. Faupel, whereby Dr. Faupel agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $660,895 for a $207,111 promissory note dated September 4, 2018. On July 20, 2018, the Company entered into an exchange agreement with Dr. Cartwright, whereby Dr. Cartwright agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,499 for a $319,000 promissory note dated September 4, 2018 that incurs interest at a rate of 6% per annum. On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement and to modify the terms of the original exchange agreement. Under this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement. On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. For Dr. Faupel the principal amount on the new note was $153,178, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. The modifications extended the maturity date on both of the notes. On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F2 Preferred Stock, respectively. The table below summarizes the detail of the exchange agreement: For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven in prior years (454 ) Amount exchanged for Series F-2 Preferred Stock (85 ) Total interest accrued through December 31, 2021 39 Balance outstanding at December 31, 2021 $ 161 Interest accrued through September 30, 2022 7 Balance outstanding at September 30, 2022 $ 168 For Dr. Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven in prior years (1,302 ) Amount exchanged for Series F-2 Preferred Stock (100 ) Total interest accrued through December 31, 2021 62 Balance outstanding at December 31, 2021 $ 281 Interest accrued through June 30, 2022 12 Balance outstanding at September 30, 2022 $ 293 On June 22, 2022, we entered into exchange agreements with Dr. Cartwright and Dr. Faupel. Pursuant to the agreements, $29,776 of related-party payables, $31,285 of short-term related-party debt and $8,939 of accrued expenses owed to these executives will be converted into shares of common stock and/or warrants valued at $70,000, upon successful completion of a financing of at least $4,000,000. On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 share of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), and a $150,000 unsecured note. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and is payable in monthly installments of $3,580 for four years, with the first payment due on March 15, 2022. The effective interest rate of the note is 6.18%. During the nine months ended September 30, 2022, Mr. Fowler forgave $43,057 of the outstanding balance of deferred compensation and may forgive up to $216,604 of the remaining deferred compensation if the Company complies with the repayment plan described above. The reduction in the outstanding balance met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. The outstanding principal amount owed on the note was $128,684 as of September 30, 2022, of which $36,286 is included in “Current portion of long-term debt, related parties” and the remainder of which is included in “Long-term debt, related parties” on the consolidated balance sheets. Future debt obligations as of September 30, 2022 for debt owed to related parties are as follows (in thousands): Year Amount 2022 $ 10 2023 498 2024 39 2025 41 2026 2 Total $ 590 As of September 30, 2022, $497,170 of the debt owed to related parties is included in “Current portion of long-term debt, related parties” and $92,399 is included in “Long-term debt, related parties” within the unaudited consolidated balance sheet. As of December 31, 2021, the outstanding debt owed was included in “Long-term debt, related parties” within the consolidated balance sheet. Small Business Administration Loan On May 4, 2020, the Company received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. The loan accrued interest at a rate of 1.00%, and matured in 24 months, with the principal and interest payments being deferred until the date of forgiveness with interest accruing, then converting to monthly principal and interest payments, at the interest rate provided herein, for the remaining eighteen (18) months. During the year ended December 31, 2021, $23,976 of the loan balance was forgiven. As of September 30, 2022 and December 31, 2021, the outstanding balance was nil and $11,181, respectively, and is included in “Current portion of long-term debt” within the consolidated balance sheets. Accrued interest on the note was nil and $385 as of September 30, 2022 and December 31, 2021, respectively. 10% Senior Unsecured Convertible Debenture On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which mature on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into common stock shares at the holder’s option, at a price of $0.50 per common stock share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) upon successful uplist to a U.S. National Exchange, the note will automatically convert into the uplisting financing; 3) each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into common shares, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into common shares at the Conversion Price; 5) Subject to a holder’s option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the common shares is $1.50 per common share or more for each trading day over a 30 consecutive trading day period, the Company may, at any time (the “Redemption Date”), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering common shares to the holders of Convertible Debentures at a deemed price of $0.50 per common share that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures. At September 30, 2022 and December 31, 2021, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and total accrued interest was $28,878 and $73,326, respectively. The bond payable discount and unamortized debt issuance costs as of September 30, 2022 and December 31, 2021 are presented below (in thousands): Senior Secured Convertible Debenture September 30, 2022 December 31, 2021 10% Senior Unsecured Convertible Debentures $ 1,130 $ 1,130 Debt Issuance costs to be amortized (48 ) (69 ) Debt Discount (165 ) (241 ) Senior Secured Convertible Debenture $ 917 $ 820 As of September 30, 2022 and December 31, 2022, the entire balance of the Senior Secured Convertible Debenture is included in “Long-term convertible debt” within the unaudited consolidated balance sheet. 6% Unsecured Promissory Note On July 9, 2020, we entered into an exchange agreement with Mr. Bill Wells (a former employee). In lieu of agreeing to dismiss approximately half of what was owed to him, or $220,000, Mr. Wells received the following: (i) cash payments of $20,000; (ii) an unsecured promissory note in the amount of $90,000 to be executed within 30 days of completing new financing(s) totaling at least $3.0 million, (iii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (ii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid. During the year ended December 31, 2021, the Company closed a financing round that exceeded the $3.0 million threshold and issued an unsecured promissory note in the amount of $97,052 to Mr. Wells. The note, for which monthly installment payments of $5,000 are due, matures 18 months after the issuance date and incurs interest at a rate of 6.0% per annum. During the nine months ended September 30, 2022, the Company made payments of $65,000 to Mr. Wells, which resulted in forgiveness of $65,000 of the remaining balance of accrued compensation. The reduction in the outstanding balance met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of September 30, 2022, the outstanding principal balance on the note was $32,052, and is included in “Current portion of long-term debt” within the consolidated balance sheets. As of December 31, 2021, the outstanding balance on the note was $97,052, of which $75,000 was included in “Current portion of long-term debt” and $22,052 was included in “Long-term debt.” As of September 30, 2022 and December 31, 2021, accrued interest on the note was $4,733 and $2,106, respectively.

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE	9 Months Ended
	Sep. 30, 2022
INCOME (LOSS) PER COMMON SHARE
INCOME (LOSS) PER COMMON SHARE	11. INCOME (LOSS) PER COMMON SHARE Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year. Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C1, Series C2, Series D, Series E, Series F and Series F-2 convertible preferred stock, Series G preferred stock, convertible debt, convertible preferred dividends and warrants convertible into common stock shares. The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data): (in thousands) September 30, 2022 2021 Net loss (3,115 ) (1,922 ) Basic weighted average number of shares outstanding 27,335 13,291 Net loss per share (basic) (0.11 ) (0.14 ) Diluted weighted average number of shares outstanding 27,335 13,291 Net loss per share (diluted) (0.11 ) (0.14 ) Dilutive equity instruments (number of equivalent units): Stock options 982 2,252 Preferred stock 6,932 17,837 Convertible debt 1,092 908 Warrants 14,086 16,979 Total Dilutive instruments 23,092 37,976 For period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt are anti-dilutive. Troubled Debt Restructurings - 2022 During the nine months ended September 30, 2022, four of the Company’s creditors forgave $344,584 of debt. The reductions in the outstanding balances met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of September 30, 2022, the troubled debt restructurings in total decreased the net loss by $344,584, or $0.01 per share. Troubled Debt Restructurings - 2021 As provided in the preceding footnotes, several transactions met the basic criteria for troubled debt, which are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt. As of September 30, 2021, the total troubled debt restructuring decreased the net loss by $85,000, or $0.01 per share.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS Amendment to Auctus Exchange Agreement On October 18, 2022, the Company and Auctus entered into an amendment to the Exchange Agreement signed on September 1, 2022. Pursuant to the amendment, the Company and Auctus agreed to execute the exchange of equity instruments on October 11, 2022. In satisfaction of the amended agreement, the Company issued 3.9 million common shares, 3.9 million warrants with an exercise price of $0.50, and 3.9 million warrants with an exercise price of $0.65 to Auctus. The newly issued warrants (“New Warrants”) will have a term of 4 years. The difference between the fair value of the warrants exchanged and the New Warrants will be recorded as a gain on extinguishment of debt in the fourth quarter of 2022. Sales of Securities Subsequent to September 30, 2022, the Company entered into certain Securities Purchase Agreements with two accredited investors, pursuant to which the Company issued 75,000 shares of its common stock, four year warrants to purchase an aggregate of 75,000 shares of Common Stock at $0.50 per share and 75,000 shares of Common Stock at $0.65 per share for an aggregate purchase price of $37,500. Additional Common Stock Issuances On October 6, 2022, the Company issued 60,000 common shares for the conversion of 15 Series F Preferred shares. On October 10, 2022, the Company issued 778 common shares for Series F Preferred dividends. On October 21, 2022, the Company issued 1,124,500 common shares for the conversion of 562.25 Series C2 Preferred Shares

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.
Accounting Standards Update	A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.
Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Accounts Receivable	The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable.
Concentrations of Credit Risk	The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Inventory Valuation	All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. The following is a summary of the Company’s inventories as of September 30, 2022 and December 31, 2021: (in thousands) September 30, December 31, 2022 2021 Raw materials $ 1,274 $ 1,255 Work-in-progress 70 69 Finished goods 37 32 Inventory reserve (785 ) (785 ) Total inventory $ 596 $ 571 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.
Property and Equipment	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. The following is a summary of the Company’s property and equipment at September 30, 2022 and December 31, 2021: (in thousands) September 30, December 31, 2022 2021 Equipment $ 1,085 $ 1,048 Software 653 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress - 8 Subtotal 1,791 1,761 Less accumulated depreciation (1,749 ) (1,747 ) Property, equipment and leasehold improvements, net $ 42 $ 14 Depreciation expense related to property and equipment for the three and nine months ended September 30, 2022 and 2021 was not material.
Debt Issuance Costs	Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.
Patent Costs (Principally Legal Fees)	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three and nine months ended September 30, 2022 and 2021.
Leases	A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 – Commitments and Contingencies.
Accrued Liabilities	Accrued liabilities as of September 30, 2022 and December 31, 2021 are summarized as follows: (in thousands) September 30, 2022 December 31, 2021 Compensation $ 488 $ 621 Professional fees 126 98 Stock subscription payable - 351 Interest 182 261 Vacation 42 39 Preferred dividends 190 349 Other accrued expenses 22 49 Total $ 1,050 $ 1,768
Stock Subscription Payable	Cash received from investors for common stock shares that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.
Revenue Recognition	ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the nine-month periods ended September 30, 2022 or 2021. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of September 30, 2022 and December 31, 2021, deferred revenue was $509,101 and $337,315, respectively.
Significant Distributors	As of September 30, 2022, accounts receivable outstanding was approximately $77,634. The gross outstanding amount was netted against a $48,172 allowance, leaving a balance of $29,462 which was from two distributors. As of December 31, 2021, accounts receivable outstanding was $171,153; the outstanding amount was netted against a $125,584 allowance, leaving a balance of $45,569, which was from two distributors.
Research and Development	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
Income Taxes	The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2021 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At September 30, 2022, the Company had approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.
Warrants	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.
Stock Based Compensation	The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation – Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future.
Derivatives	The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
SIGNIFICANT ACCOUNTING POLICIES
Inventory valuation	(in thousands) September 30, December 31, 2022 2021 Raw materials $ 1,274 $ 1,255 Work-in-progress 70 69 Finished goods 37 32 Inventory reserve (785 ) (785 ) Total inventory $ 596 $ 571
Property and equipment	(in thousands) September 30, December 31, 2022 2021 Equipment $ 1,085 $ 1,048 Software 653 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress - 8 Subtotal 1,791 1,761 Less accumulated depreciation (1,749 ) (1,747 ) Property, equipment and leasehold improvements, net $ 42 $ 14
Accrued liabilities	(in thousands) September 30, 2022 December 31, 2021 Compensation $ 488 $ 621 Professional fees 126 98 Stock subscription payable - 351 Interest 182 261 Vacation 42 39 Preferred dividends 190 349 Other accrued expenses 22 49 Total $ 1,050 $ 1,768

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS
Schedule of fair value for liabilities measured on a recurring basis	Fair Value at September 30, 2022 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $328,941 loan on December 17, 2019 $ - $ - $ (19 ) $ (19 ) Total short-term liabilities at fair value $ - $ - $ (19 ) $ (19 ) Fair Value at December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (32 ) (32 ) Total long-term liabilities at fair value $ - $ - $ (32 ) $ (32 )
Summary of changes to Level 3 instruments	(in thousands) Senior Secured Derivative Total Balance, December 31, 2021 $ - $ (32 ) $ (32 ) Change in fair value during the period - 13 13 Balance, September 30, 2022 $ - $ (19 ) $ (19 )

STOCKHOLDERS DEFICIT (Tables)

STOCKHOLDERS DEFICIT (Tables)	9 Months Ended
	Sep. 30, 2022
STOCKHOLDERS DEFICIT:
Common stock issued	Number of Shares Issuances of common stock to investors 6,636,540 Issuances of common stock for warrants exercised 5,127,923 Issuances of common stock for payment of Series D Preferred dividends 64,979 Issuances of common stock for payment of Series E Preferred dividends 179,858 Issuances of common stock for payment of Series F Preferred dividends 162,436 Issuances of common stock for payment of Series F-2 Preferred dividends 114,304 Issuances of common stock for payment of interest 241,914 Issuances of common stock for Series F one-time 15% dividend 255,401 Issuances of common stock for Series F-2 one-time 15% dividend 368,505 Conversion of Series D Preferred stock to common stock 975,000 Conversion of Series E Preferred stock to common stock 3,390,000 Conversion of Series F Preferred stock to common stock 1,420,000 Conversion of Series F-2 Preferred stock to common stock 10,808,000 Issued during the nine months ended September 30, 2022 29,744,860 Summary table of common stock share transactions: Shares outstanding at December 31, 2021 13,673,583 Issued in 2022 29,744,860 Shares outstanding at September 30, 2022 43,418,443
Fair value of the warrants issued	September 30, 2022 Expected term (years) 3.8 Years Volatility 151.19 % Risk-free interest rate 3.30 % Dividend yield 0.00 %
Outstanding warrants to purchase common stock	Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2021 27,669,634 $ 0.29 Warrants issued 15,323,080 0.54 Warrants expired (1,000 ) 0.50 Warrants exercised (2,934,324 ) 0.17 Outstanding, September 30, 2022 40,057,390 $ 0.40

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2022
STOCK OPTIONS
Stock option activity	Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of September 30, 2022 1,500,000 $ 0.49 7.8 years $ - Options exercisable as of September 30, 2022 1,227,136 $ 0.49 7.8 years $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2022
COMMITMENTS AND CONTINGENCIES
Operating lease right-of-use assets and lease liabilities	(in thousands) September 30, 2022 Operating lease right-of-use assets $ 321 Operating lease liabilities $ 343
Maturities of operating lease liabilities	(in thousands) Operating Lease Payments 2022 (remaining) $ 27 2023 112 2024 115 2025 118 2026 50 Total future lease payments 422 Less: discount (79 ) Total lease liabilities $ 343
Weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities	Nine Months Ended September 30, 2022 Weighted average remaining lease term (years) 3.7 Weighted average discount rate 11.4 %

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2022
NOTES PAYABLE (Tables)
Short-term notes payable, including related parties	Short-term notes payable, including related parties September 30, 2022 December 31, 2021 Dr. Cartwright $ 17 $ 34 Mr. Fowler - 6 Premium Finance (insurance) 90 48 Short-term notes payable $ 107 $ 88

AUCTUS CONVERTIBLE DEBT (Tables

AUCTUS CONVERTIBLE DEBT (Tables)	9 Months Ended
	Sep. 30, 2022
AUCTUS CONVERTIBLE DEBT
Schedule of Auctus convertible notes payable	September 30, 2022 December 31, 2021 Auctus Tranche 2 $ 329 $ 400 Auctus prepayment penalty 350 350 Auctus (March 31, 2020 Note) - 161 Debt discount and issuance costs to be amortized - (14 ) Auctus convertible notes payable $ 679 $ 897

LONG TERM DEBT (Tables)

LONG TERM DEBT (Tables)	9 Months Ended
	Sep. 30, 2022
LONG TERM DEBT
Long-term debt, related parties	For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven in prior years (454 ) Amount exchanged for Series F-2 Preferred Stock (85 ) Total interest accrued through December 31, 2021 39 Balance outstanding at December 31, 2021 $ 161 Interest accrued through September 30, 2022 7 Balance outstanding at September 30, 2022 $ 168 For Dr. Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven in prior years (1,302 ) Amount exchanged for Series F-2 Preferred Stock (100 ) Total interest accrued through December 31, 2021 62 Balance outstanding at December 31, 2021 $ 281 Interest accrued through June 30, 2022 12 Balance outstanding at September 30, 2022 $ 293
Future debt related parties obligations	Year Amount 2022 $ 10 2023 498 2024 39 2025 41 2026 2 Total $ 590
Bond payable discount and unamortized debt issuance costs	Senior Secured Convertible Debenture September 30, 2022 December 31, 2021 10% Senior Unsecured Convertible Debentures $ 1,130 $ 1,130 Debt Issuance costs to be amortized (48 ) (69 ) Debt Discount (165 ) (241 ) Senior Secured Convertible Debenture $ 917 $ 820

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE (Tables)	9 Months Ended
	Sep. 30, 2022
INCOME (LOSS) PER COMMON SHARE
Earnings per share	(in thousands) September 30, 2022 2021 Net loss (3,115 ) (1,922 ) Basic weighted average number of shares outstanding 27,335 13,291 Net loss per share (basic) (0.11 ) (0.14 ) Diluted weighted average number of shares outstanding 27,335 13,291 Net loss per share (diluted) (0.11 ) (0.14 ) Dilutive equity instruments (number of equivalent units): Stock options 982 2,252 Preferred stock 6,932 17,837 Convertible debt 1,092 908 Warrants 14,086 16,979 Total Dilutive instruments 23,092 37,976

ORGANIZATION BACKGROUND AND B_2

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Decrease in authorized common share			500,000,000
Accumulated deficit	145,500,000
Total stockholders' deficits	$ 2,700
Working capital	1,800
Net loss including preferred dividend	3,100
Proceeds from sale of common stock	3,200
Proceeds from exercise of warrants	$ 495	$ 0
Warrants [Member] | Minimum
Warrants exercise price per share	$ 0.15
Warrants [Member] | Maximum
Warrants exercise price per share	$ 0.80
Warrants [Member] | Exchange Agreement With GPB [Member]
Warrants exercisable for common stock outstanding	40,100,000
Exercise of the in money warrants	$ 8,600

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Raw materials	$ 1,274	$ 1,255
Work in process	70	69
Finished goods	37	32
Inventory reserve	(785)	(785)
Total	$ 596	$ 571

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Less accumulated depreciation and amortization	$ (1,749)	$ (1,747)
Property and equipment, net	42	14
Subtotal	1,791	1,761
Furniture and Fixtures
Property and equipment, gross	41	41
Construction in Progress [Member]
Property and equipment, gross	0	8
Equipment
Property and equipment, gross	1,085	1,048
Software
Property and equipment, gross	653	652
Leasehold Improvement
Property and equipment, gross	$ 12	$ 12

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Compensation	$ 488	$ 621
Professional fees	126	98
Stock Subscription Payable	0	351
Interest	182	261
Vacation	42	39
Preferred dividends	190	349
Other accrued expenses	22	49
Total	$ 1,050	$ 1,768

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Accounts receivable outstanding	$ 77,634	$ 171,153
Accounts receivable, net of allowance	48,172	125,584
Deferred revenue	509,101	337,315
Remaining balance	29,462	$ 45,569
Net operating loss carry forward	$ 61,600,000
Percentage amount of tax benefit	50%

FAIR VALUE OF FINANCIAL INSTR_3

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Derivative liability	$ (19)	$ (32)
Level 1
Derivative liability	0	0
Level 2
Derivative liability	0	0
Level 3
Derivative liability	(19)	(32)
Auctus Loan
Derivative liability	(19)	(32)
Auctus Loan | Level 1
Derivative liability	0	0
Auctus Loan | Level 2
Derivative liability	0	0
Auctus Loan | Level 3
Derivative liability	$ (19)	$ (32)

FAIR VALUE OF FINANCIAL INSTR_4

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - USD ($)	1 Months Ended	9 Months Ended
	Jun. 22, 2022	Sep. 30, 2022
Change in fair value during the year	$ 70,000
Level 3
Beginning Balance, Warrants		$ (32,000)
Change in fair value during the year		13,000
Ending Balance, Warrants		(19,000)
Level 3 | Derivative
Beginning Balance, Warrants		(32,000)
Change in fair value during the year		13,000
Ending Balance, Warrants		(19,000)
Level 3 | Senior Secured Debt
Beginning Balance, Warrants		0
Change in fair value during the year		0
Ending Balance, Warrants		$ 0

FAIR VALUE OF FINANCIAL INSTR_5

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative)	Sep. 30, 2022 USD ($)
FAIR VALUE OF FINANCIAL INSTRUMENTS
Derivative liability	$ 298,884

STOCKHOLDERS DEFICIT (Details)

STOCKHOLDERS DEFICIT (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2020
STOCKHOLDERS DEFICIT:
Issuance of common stock to investors	6,636,540
Issuance of common stock for warrants exercised	5,127,923
Issuance of common stock for payment of Series D preferred dividends	64,979
Issuance of common stock for payment of Series E preferred dividends	179,858
Issuance of common stock for payment of series F Preferred dividends	162,436
Issuance of common stock for payment of Series F-2 preferred dividends	114,304
Issuance of common stock for payment of interest	241,914
Issuance of common stock for Series F one-time 15% dividend	255,401
Issuance of common stock for Series F-2 one-time 15% dividend	368,505
Conversion of Series D Preferred stock to common stock	975,000
Conversion of Series E preferred stock to common stock	3,390,000
Conversion of Series F Preferred shares into common stock	1,420,000
Conversion of Series F-2 Preferred stock to common stock	10,808,000
Issued during the nine months ended September 30, 2022	29,744,860
Share issued	29,744,860
Outstanding	43,418,443	13,673,583

STOCKHOLDERS DEFICIT (Details 1

STOCKHOLDERS DEFICIT (Details 1)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
STOCKHOLDERS DEFICIT:
Warrants outstanding, beginning | shares	27,669,634
Warrants issued | shares	15,323,080
Warrants expired | shares	(1,000)
Warrants exercised | shares	(2,934,324)
Warrants outstanding | shares	40,057,390
Weighted Average Exercise Price Per Share, beginning | $ / shares	$ 0.29
Weighted average exercise price per share issued | $ / shares	0.54
Weighted average exercise price per share expired | $ / shares	0.50
Weighted Average Exercise Price Per Share, Warrants exercised | $ / shares	0.17
Weighted average exercise price per share outstanding | $ / shares	$ 0.40

STOCKHOLDERS DEFICIT (Details 2

STOCKHOLDERS DEFICIT (Details 2)	9 Months Ended
	Sep. 30, 2022
SIGNIFICANT ACCOUNTING POLICIES
Expected term	3 years 9 months 18 days
Volatility	151.19%
Risk free interest rate	3.30%
Dividend Yield	0%

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)				1 Months Ended		3 Months Ended	9 Months Ended
	Sep. 01, 2022	Jul. 08, 2021	Aug. 02, 2018	Feb. 28, 2021	Jan. 31, 2021	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Jun. 04, 2021	Jan. 22, 2020
Common stock, shares authorized						500,000,000	500,000,000	500,000,000
Shares of common stock issued	6,636,540
Aggregate shares of common stock	$ 6,636,540
Price per share	65,000
Aggregate purchase price	$ 3,318,270
Common shares for warrants exercised						5,127,923	5,127,923	2,193,599
Common stock shares issued						27,583,473	27,583,473	43,418,443
Common stock shares outstanding						27,583,473	27,583,473	13,673,583
Common stock, par value						$ 0.001	$ 0.001	$ 0.001
Issuance of the common shares							29,744,860
Common Stock issued							29,744,860
Preferred stock shares converts into common stock							1,420,000
Strike price										$ 0.25
Warrants issued to investors						13,273,080
Warrants issued to consultant						2,050,000
Received from the stock holders							$ 351,000
Interest expense						$ 182,000	$ 182,000	$ 261,000
Series F-2 Convertible Preferred Shares
Price per share							2,559
Preferred stock shares converts into common stock							4,000
Convertible common stock						$ 4,000	$ 4,000
Company issued common stock						10,808,000	10,808,000
Preferred stock, par value						$ 0.001	$ 0.001	$ 0.001
Percentage of dividend							6%
Conversion price per share							$ 0.25
Preferred stock shares designated						3,500	3,500
Liquidation preference						$ 3,237	$ 3,237
Preferred stock shares issued						53,500	53,500
Increased beneficial ownership percentage							9.99%
Common Stock primary trading shares exceed							1,000
Exceeds percentage							200%
Preferred stock shares outstanding						2,800	2,800	3,237
Conversion beneficial ownership limitation							0.04%
Maturity period							5 years
Accrued dividend amount						$ 123,743	$ 123,743
Additional stock issued during period for payment of non recurring dividend							368,505
Cumulative dividends at the rate							0.06%
Series F-2 Preferred stock coversion shares							466
Series F-2 Preferred Stock dividends shares							114,304
Preferred stock shares received						678,000	678,000
Stated value of preference share						$ 1,000	$ 1,000
Accrued dividends of preferred shares						$ 16,242	16,242
outstanding debt							$ 2,559,000
Non recurring dividend percent							0.15%
Preferred stock shares issued						500	500	3,200
Preferred stock shares outstanding						500	500	3,200
Series G Convertible Preferred Shares
Preferred stock, par value						$ 0.001	$ 0.001	$ 0.001
Cumulative dividends at the rate							0.08%
Preferred stock, authorized						1,000	1,000	1,000,000
Preferred stock shares issued						0	0	0
Preferred stock shares outstanding						0	0	0
Investment net						$ 114,597	$ 114,597
Preferred stock redeemed				62,000	91,000
Preferred stock shares outstanding						0	0	0
Series G Convertible Preferred Shares | Power Up Lending Group Ltd [Member]
Cumulative dividends at the rate				0.08%	0.08%
Accrued dividends of preferred shares								$ 114,597
Investment net				$ 53,500	$ 78,500	$ 78,500	$ 78,500
Preferred stock redeemed			925,000	925,000			925,000
Investment amount				$ 62,000
Total investment amount						75,000	$ 75,000
Additional Series G preferred stock shares, amount				$ 50,000	$ 75,000
Additional tranches of financing						$ 925,000	$ 925,000
Discount rate						0.19%	0.19%
Discounted rate				0.19%
Redemption of february 2021 investment, amount		$ 78,094
Difference of interest expense		$ 28,094
Interest expense									$ 39,597
Conversion beneficial ownership limitation				0.04%	0.04%
Increased election holders				0.09%	0.09%
Corresponding percentage Description				1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%.	1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%
Net proceeds							$ 125,000
Outstanding amount						$ 50,000	$ 50,000
Preferred Stock [Member]
Preferred stock, par value						$ 0.001	$ 0.001
Series E Preferred Shares
Preferred stock, par value						$ 0.001	0.001
Conversion price per share							$ 0.25
Preferred stock shares designated						5,000	5,000
Liquidation preference						$ 888	$ 888	$ 1,736
Common Stock primary trading shares exceed							1,000
Exceeds percentage							200%
Conversion beneficial ownership limitation							0.04%
Maturity period							5 years
Preferred stock stated value						$ 1,000	$ 1,000
Common stock shares issued for preferred stock dividends							179,858
Accrued dividends						$ 12,654	$ 12,654
Issuance of common stock for conversion of Series E Convertible Preferred Stock							3,390,000
Increased election holder							0.09%
Series C1 Convertible Preferred Shares
Preferred stock shares converts into common stock							2,000
Conversion price per share							$ 0.50
Preferred stock shares designated						20,250	20,250
Preferred stock shares issued						1,049	1,049	1,049
Preferred stock shares outstanding						1,049	1,049	1,049
Preferred stock shares surrendered							3,262
Total convertible of common stock shares							2,098,500
Series D Preferred Shares
Preferred stock shares converts into common stock							975,000
Strike price						$ 0.20	$ 0.20
Conversion price per share							$ 0.25
Preferred stock shares designated						6,000	6,000
Liquidation preference						$ 763	$ 763
Increased beneficial ownership percentage							0.09%
Common Stock primary trading shares exceed							1,000
Exceeds percentage							200%
Preferred stock shares issued						763	763
Shares exchange						650,000	650,000
Warrants exchange						650,000	650,000
Proceed from excercise of warrant							$ 130,000
Preferred stock converted share						325	325
Shares issued for payment of accured stock dividend							$ 64,979
Common stock, issued public shares						1,526,000	1,526,000
Beneficial ownership percentage							4.99
Shares outstanding						438	438	763
Common stock warrants 1							1,526,000
Warrant exercise price per share							0.25
Common stock warrants							0
Common stock warrants exercise price 1							$ 0.75
Conversion of investor shares							438
Preferred stock dividends accrued							$ 8,213
Series C Convertible Preferred Shares
Preferred stock shares converts into common stock							2,000
Conversion price per share							$ 0.50
Preferred stock shares designated						9,000	9,000
Liquidation preference						$ 286	$ 286	$ 1,000
Total convertible of common stock shares			6,524,500				572,000
Dividing the stated value						$ 1,000	$ 1,000
Cumulative dividends annual rate						12%	12%
Unpaid accrued dividends							$ 120,120
Make-whole payment for converted share						200	200	200
Series F Preferred Shares
Preferred stock shares converts into common stock							4,000
Conversion price per share							$ 0.25
Preferred stock shares designated						1,500	1,500
Liquidation preference						$ 1,000	$ 1,000
Common Stock primary trading shares exceed							1,000
Exceeds percentage							200%
Conversion beneficial ownership limitation							0.04%
Maturity period							5 years
Additional stock issued during period for payment of non recurring dividend							255,401
Preferred stock shares issued						1,071	1,071	1,426
Increased election holder							0.09%
Preferred stock shares outstanding						1,436	1,436
Number of shares converted into common stock						1,420,000	1,420,000
Shares issued common stock						$ 1,436,000	$ 1,436,000
Shares converted into common stock						355	355
Cumulative dividend rate							0.06%
Issuance of common stock for payment pf annual series							162,436
Accrued dividends						$ 32,943	$ 32,943
Series C2Convertible Preferred Shares
Shares of C2 conversion price						50,000	50,000
Number of shares converted to common stock						$ 2,000	$ 2,000
Total convertible common stock						$ 6,524,000	$ 6,524,000
Dividing the stated value						1,000	1,000

STOCK OPTIONS (Details)

STOCK OPTIONS (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
STOCK OPTIONS
Outstanding at ending of year | shares	1,500,000
Number of shares exercisable | shares	1,227,136
Options outstanding weighted average outstanding price, ending | $ / shares	$ 0.49
Options exercisable weighted average exercise price | $ / shares	$ 0.49
Weighted average remaining contractual life outstanding	7 years 9 months 18 days
Weighted average remaining contractual life exercisable	7 years 9 months 18 days
Agrregate intrensic value outstanding | $	$ 0
Agrregate intrensic value exercisable | $	$ 0

STOCK OPTION (Details Narrative

STOCK OPTION (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
STOCK OPTIONS
Unrecognized stock-based compensation expense	$ 131,735
Weighted-average fair value of awards granted	$ 0.47	$ 0.47
Stock options granted outstanding common stock shares percentage	10%
Options granted expiration term	10 years
Options granted exercisable term	4 years

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
COMMITMENTS AND CONTINGENCIES
Operating lease right-of-use assets	$ 321	$ 372
Operating lease liabilities	$ 343

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 1) $ in Thousands	Sep. 30, 2022 USD ($)
COMMITMENTS AND CONTINGENCIES
2022 (remaining)	$ 27
2023	112
2024	115
2025	118
2026	50
Total future lease payments	422
Less: discount	(79)
Total lease liabilities	$ (343)

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details 2)	9 Months Ended
	Sep. 30, 2022
COMMITMENTS AND CONTINGENCIES
Weighted average remaining lease term (years)	3 years 8 months 12 days
Weighted average discount rate	11.40%

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				1 Months Ended		3 Months Ended
	Mar. 10, 2021	Sep. 06, 2016	Jun. 05, 2016	Jan. 22, 2022	Dec. 31, 2021	Sep. 30, 2022	Aug. 24, 2022	Jan. 22, 2020	Jul. 24, 2019
Consideration received									$ 885,144
Financing agreement amount					$ 1,000,000
Royalty percent			20%
Warrants								5,000,000
Warrants broken into four tranches								1,250,000
Strike price								$ 0.25
Escrow agent rate per share									$ 1.90
Shenghuo Medical, LLC [Member]
Payment receive descriptions			the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million
Shandong Yaohua Medical Instrument Corporation [Member]
Balance due for outstanding purchase order						$ 26,965
Shares exchange									12,147
Consulting Agreement [Member] | Mr. Blumberg
Warrants						875,000
expense for the warrants					$ 200,959
Terms of amendment to agreement	on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares.	royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable			the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. The Company confirmed an obligation to provide Mr. Blumberg with 950,000 fully transferrable warrants, which will expire on January 1, 2024 and have an exercise price of $0.25. Issuance of the warrants owed to Mr. Blumberg for his services is now predicated on the Company receiving funding receipts of $1,000,000
Subscription receivable	$ 350,000
Consulting Agreement [Member] | Lee Bowles
Warrants						375,000
Consulting Agreement [Member] | Black-scholes
Warrants						800,000
Recognized expense						364,800
Consulting Agreement [Member] | Binomial Lattice Model
Recognized expense						15,057
Consulting Agreement [Member] | Advisory Group
Warrants							800,000	5,000,000
Exercise price							$ 0.50
Consulting Agreement [Member] | Mr. Gruijic
Warrants							600,000
Exercise price							$ 0.75
Additional Warrants							600,000
Promotional Agreement [Member]
Consulting expenses						$ 79,444
Fair vaue of warrants				$ 715,000
Unrecognized consulting expense						$ 0
Royalty Agreement [Member]
Royalty paid description		royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable
Royalty consideration		$ 50,000

SHORT TERM NOTES PAYABLE (Detai

SHORT TERM NOTES PAYABLE (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Short term notes payable	$ 107	$ 88
Dr. Cartwright
Notes payable in default, including related parties	17	34
Mr. Fowler
Notes payable in default, including related parties	0	6
Premium Finance insurance
Notes payable in default, including related parties	$ 90	$ 48

SHORT TERM NOTES PAYABLE (Det_2

SHORT TERM NOTES PAYABLE (Details Narrative22) - USD ($)			1 Months Ended
	Jul. 04, 2022	Jul. 04, 2021	Mar. 22, 2021	Dec. 31, 2019	Sep. 30, 2022	Dec. 31, 2021	Jan. 19, 2017	Dec. 21, 2016
Short-term notes payable due to related parties					$ 17,154	$ 87,514
Line of credit, balance						39,900
Outstanding principal balance					89,947
Line of credit facility, maximum borrowing capacity	$ 123,889
Accrued interest					1,050,000	1,768,000
Short term promissory note					107,000	$ 88,000
Premium Finance Agreement [Member]
Line of credit facility, maximum borrowing capacity		$ 117,560
Monthly payment of insurance		$ 11,968
Interest and maturity date description		interest at 4.3%, until it matured in April of 2022. As of September 30, 2022
Dr. Cartwright
Line of credit, balance					17,154
Notes initially issued with interest				0%
Percentage of increased interest				6%
Promissory notes issued				$ 45,829
Financing proceeds received by company				$ 1,000,000
Mr. Fowler
Outstanding principal balance					$ 45,118		$ 13,900	$ 12,500
Annual interest rate description				The note was initially issued with 0% interest, however interest increased to 6.0% interest 90 days after the Company received $1,000,000 in financing proceeds.
Mr. Fowler | March 22, 2021 exchange agreement [Member]
Accrued interest			$ 18,718
Monthly payment of insurance			3,850
Short term promissory note			45,118
Mr. Fowler | Long-Term Debt - Related Parties
Outstanding principal balance			$ 26,400

AUCTUS CONVERTIBLE DEBT (Detail

AUCTUS CONVERTIBLE DEBT (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Convertible notes payable - short-term	$ 679	$ 897
Debt discount and issuance costs to be amortized	0	(14)
Convertible notes payable	0	161
Auctus
Convertible notes payable	0	161
Auctus Tranche 2 [Member]
Convertible notes payable	329	400
Auctus Prepayment Penalty [Member]
Convertible notes payable	$ 350	$ 350

AUCTUS CONVERTIBLE DEBT (Deta_2

AUCTUS CONVERTIBLE DEBT (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 17, 2019	Sep. 30, 2022	Sep. 01, 2022	Dec. 31, 2021
Warrants price description		warrants that are priced between $0.15 and $0.20, and for the value of $1,950,000, which includes the value of the warrant and $350,000 in early prepayment penalty, agreed to exchange it for 3,900,000 common shares, warrants to purchase 3,900,000 common shares at $0.50 per share and warrants to purchase 3,900,000 common shares at $0.65 per share (the “Exchange”). Auctus agreed the equity instruments will be issued and exchanged in the fourth quarter of 2022 (see Note 12, “Subsequent Events”). As a result of the Exchange Agreement, Auctus forgave a default penalty of $225,444
Description of variable conversion prices	The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020, the $0.15 price floor no longer applied.
Interest payable		$ 182,000		$ 261,000
Auctus Fund, LLC [Member]
Debt amount			$ 1,228,183
Prepayment penalty			350,000
Premiums			281,256
Interest payable			91,555
Debt owed			710,911
Repayment debt			$ 221,467
Debt description		Auctus pursuant to the terms of the Exchange Agreement (the “Repayment”), of which $161,184 was applied to principal and penalties and $60,283 was applied to interest payable. Following the Exchange and Repayment, the Company will make payments to Auctus in four installments, over an 18-month period. The first installment of $125,000 was paid on September 8, 2022, of which $101,116 was applied to outstanding principal and $23,884 was applied to interest payable. The transaction was accounted for in accordance with ASC 470-60, Troubled Debt Restructurings (“TDR”) by Debtors. As a result of the Exchange Agreement, the Company recorded a gain on extinguishment of debt of $186,527 during the three months ended September 30, 2022
Total balance debt		$ 579,000		$ 161,000
Warrants		8,775,000
Total Convertible note issued	$ 2,400,000

LONG TERM DEBT (Details)

LONG TERM DEBT (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Bonus	$ 488,000	$ 621,000
Amount forgiven in prior years	(344,584)
Vacation	42,000	39,000
Dr. Cartwright
Salary		337,000
Bonus		675,000
Loans to Company		528,000
Interest on loans		81,000
Total outstanding prior to exchange		1,621,000
Amount forgiven in prior years		(1,302,000)
Amount exchanged for Series F-2 Preferred Stock		(100,000)
Total interest accrued through December 31, 2021		62,000
Balance outstanding at September 30, 2022	12,000
Balance outstanding, end of period	293,000	281,000
Dr. Faupel
Salary		134,000
Bonus		20,000
Loans to Company		196,000
Interest on loans		149,000
Total outstanding prior to exchange		661,000
Amount forgiven in prior years		(454,000)
Amount exchanged for Series F-2 Preferred Stock		(85,000)
Total interest accrued through December 31, 2021		39,000
Balance outstanding at September 30, 2022	7,000
Balance outstanding, end of period	$ 168,000	161,000
Vacation		95,000
Interest on compensation		$ 67,000

LONG TERM DEBT (Details 1)

LONG TERM DEBT (Details 1) $ in Thousands	Sep. 30, 2022 USD ($)
Total	$ 590
Long-Term Debt - Related Parties | Mr. Fowler
2022	10
2023	498
2024	39
2025	41
2026	$ 2

LONG TERM DEBT (Details 2)

LONG TERM DEBT (Details 2) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
LONG TERM DEBT
10% Senior Unsecured Convertible Debentures	$ 1,130	$ 1,130
Debt Issuance costs to be amortized	(48)	(69)
Debt Discount	(165)	(241)
Long-term convertible debt	$ 917	$ 820

LONG TERM DEBT (Details Narrati

LONG TERM DEBT (Details Narrative) - USD ($)		1 Months Ended					12 Months Ended
	May 04, 2020	Jun. 22, 2022	Dec. 31, 2021	May 17, 2021	Mar. 22, 2021	Feb. 19, 2021	Dec. 31, 2021	Sep. 30, 2022	Jul. 09, 2020	Sep. 04, 2018
Purchase agreement		$ 29,776
Short-term related-party debt		31,285
Notes payable to current related party								$ 497,170
Accrued expenses		8,939
Long-term debt related parties		92,399
Financing lease		4,000,000
Common stock or warrants valued		$ 70,000
Current portion of long-term debt								32,052
Interest payable			$ 261,000				$ 261,000	182,000
Current portion of long-term debt			88,000				88,000	32,000
6% Unsecured Promissory Note
Interest payable			2,106				2,106	4,733
Current portion of long-term debt			75,000				75,000
Long term debt			22,052
Outstanding balance			97,052
10% Senior Unsecured Convertible Debenture
Interest payable			73,326				73,326	$ 28,878
Convertible debentures right description				each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023
Change of Control premium percentage				3%
Senior Secured Convertible rate								10%
Deemed price				$ 0.50
Convertible debentures			1,130,000	$ 1,000			1,130,000
Debt maturity date				May 17, 2024
Proceeds from convertible debenture				$ 1,130,000
Conversion price				$ 0.50
Paycheck Protection Program
Interest payable			385				385	$ 385
Loan balance							23,976
Current portion of long-term debt			11,181				11,181	0
Loan maturity term	24 years
Proceeds from loan	$ 50,184
Loan interest rate	1%
Dr. Cartwright
Total outstanding prior to exchange			1,621,000				1,621,000
Promissory note interest rate						6%
Debt instrument converted amount						$ 85,000
Series F-2 Preferred Stock issued upon conversion of debt						100
Principal amount of promissory note						$ 267,085
Issuance of promissory note in exchange of related party debt										$ 319,000
Loans, interest, bonus, salary and vacation paid amount										$ 1,621,499
Interest rate per annum										6%
Promissory note maturity date						Feb. 18, 2023
Salary			337,000				337,000
Mr. Fowler
Total outstanding prior to exchange								128,684
Long-term debt-related parties								36,286
Due to related party					$ 546,214			43,057
Promissory note interest rate					6%
Debt instrument converted amount					$ 65,000
Series F-2 Preferred Stock issued upon conversion of debt					50
Interest payable					$ 133,590
Due to related party, amount					$ 546,214
Promissory note default interest rate					18%
Promissory note monthly installment					$ 3,580
Preferred shares converted into common stock					200,000
Effective interest rate					6.18%
Deferred salary					$ 412,624			216,604
Unsecured note issued upon conversion of debt					$ 150,000
Dr. Faupel
Total outstanding prior to exchange			661,000				661,000
Due to related party										$ 660,895
Promissory note interest rate						6%
Debt instrument converted amount						$ 100,000
Series F-2 Preferred Stock issued upon conversion of debt						85
Principal amount of promissory note						$ 153,178
Issuance of promissory note in exchange of related party debt										$ 207,111
Salary			134,000				134,000
Mr. Bill Wells
Total outstanding prior to exchange			$ 97,052				97,052		$ 90,000
Promissory note interest rate			6%
Common share stock option									66,000
Salary									$ 220,000
Amount paid									$ 110,000
Exercise price									$ 0.49
Received cash payment								$ 65,000	$ 20,000
Total amount to be receive			$ 3,000,000				3,000,000		3,000,000
Monthly payment due			$ 5,000				$ 5,000		$ 3,667

INCOME (LOSS) PER COMMON SHAR_2

INCOME (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net loss	$ (1,054)	$ (51)	$ (3,115)	$ (1,922)
Basic weighted average number of shares outstanding			27,335	13,291
Net loss per share (basic)			$ (0.11)	$ (0.14)
Diluted weighted average number of shares outstanding			27,335	13,291
Net loss per share (diluted)			$ (0.11)	$ (0.14)
Total dilutive instruments			$ 23,092	$ 37,976
Warrants [Member]
Dilutive equity instruments (number of equivalent units):
Dilutive equity instruments (number of equivalent units)			14,086	16,979
Convertible Debt [Member]
Dilutive equity instruments (number of equivalent units):
Dilutive equity instruments (number of equivalent units)			1,092	908
Preferred Stock [Member]
Dilutive equity instruments (number of equivalent units):
Dilutive equity instruments (number of equivalent units)			6,932	17,837
Stock Option [Member]
Dilutive equity instruments (number of equivalent units):
Dilutive equity instruments (number of equivalent units)			982	2,252

INCOME (LOSS) PER COMMON SHAR_3

INCOME (LOSS) PER COMMON SHARE (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
INCOME (LOSS) PER COMMON SHARE
Decrease in net loss	$ 344,584	$ 85,000
Account payable forgivness amount	$ 344,584
Price of share	1,000	1,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 11, 2022	Oct. 21, 2022	Oct. 10, 2022	Sep. 30, 2022
Aggregate shares of common stock to purchase price				$ 75,000
Price per share				50,000
Share price of common stock				$ 65,000
Issuance of common stock				75,000
Subsequent Event Member
Issuance of common stock	3,900,000
Term of warrants	4 years
Warrants with an exercise price	50,000
Series F Preferred Shares
Common shares issued for conversion			$ 60,000
Common shares for preferred dividends			$ 778
Series C2 Preferred Shares [Member]
Common shares issued		1,124,500
Conversion of common preferred shares		562